CLAIM CARD
The evidence base for immune and inflammatory outcomes in the context of ARBs and longevity is anchored by a single randomized, double-blinded, placebo-controlled pilot clinical trial. Lu 2025 reported. The trial population consisted of adults in an observational cohort design, assessing changes in systemic inflammation and the renin-angiotensin system. This study provides the primary direct evidence from a controlled human intervention relevant to this outcome class.
Evidence grade: exploratory
Contradiction status: none
Publication: edeb045d-18ed-49dc-95b6-57f76783ce2b
Provenance: Derivation Web chain
Citation Support
source_1Solomon 2026source_2Din 2026source_3Li 2025source_4Mei 2025source_5Chung 2024